- Company
- JAKi Civinqo completes pricing negotiations for reimb in KOR
- by Eo, Yun-Ho Jun 22, 2023 05:40am
- The atopic dermatitis treatment ‘Cibinqo’ may be listed for reimbursement in Korea from July. According to industry sources, Pfizer Korea completed the pricing negotiations for its new JAK1 inhibitor drug Cibinqo (abrocitinib) with the National Health Insurance Service. Drugs that pass the Health Insurance Policy Deliberative Committee (
- Company
- Joint development & production of DM Combi with SK Chem & AZ
- by Kim, Jin-Gu Jun 21, 2023 10:06am
- SK Chemicals plans to supply products developed and produced to 12 global countries through AZ. SK Chemicals announced on the 19th that it has produced the first commercial product of a diabetes complex jointly developed with AstraZeneca. SK Chemicals explained that it recently held an event to inspect and celebrate the global joint busin
- Company
- Camzyos, which prevents sudden cardiac death in young people
- by Jung, Sae-Im Jun 21, 2023 05:51am
- Korea BMS Pharmaceuticals (CEO Lee Hye-young) announced on the 20th that it held a domestic approval meeting for Camzyos, a treatment for 'obstructive hypertrophic cardiomyopathy (oHCM)', on the 19th and introduced its clinical value. Obstructive hypertrophic cardiomyopathy is a severe and rare heart disease in which thickened left ventricular m
- Company
- [two thousandth]Toxins accumulated in Soyul's body every day
- by Jung, Sae-Im Jun 21, 2023 05:50am
- Soyul, who turned 5 this year, stopped growing at 80cm and is no longer growing. Her arms and legs are not straight and straight. If you try to forcefully stretch it, you could break a bone. This is because Soyul's bone density is low enough to be found in an elderly person in his 80s. Soyul also has carpal tunnel syndrome, which affects 7
- Company
- ALS drug Teglutik may be prescribed at general hospitals
- by Eo, Yun-Ho Jun 20, 2023 05:35am
- SK Chemical’s Lou Gehrig's disease treatment ‘Teglutik’ can now be prescribed at general hospitals in Korea. According to industry sources, Teglutik (riluzole) passed the drug committees (DCs) of tertiary hospitals including Samsung Medical Center, Seoul National University Hospital, Asan Medical Center, as well as medical institution
- Company
- SK Biopharmaceuticals’ Cenobamate approved in Canada
- by Chon, Seung-Hyun Jun 19, 2023 06:00am
- SK Biopharmaceuticals announced on the 15th that Cenobamate, a new drug for epilepsy, has received marketing approval from the Canadian Department of Health. Cenobamate's commercialization in Canada is being handled by Paladin Labs, a local pharmaceutical company. Cenobamate is a new drug for epilepsy that SK Biopharmaceuticals is independently
- Company
- ADHD drug Strattera discontinues supply in Korea
- by Kim, Jin-Gu Jun 19, 2023 06:00am
- The domestic supply of the ADHD (Attention-Deficit·Hyperactivity Disorder) treatment ‘Strattera (atomoxetine) was completely discontinued in Korea. Its supplier Lilly Korea said, “We have currently discontinued its supply, with no plans for resupply. According to the pharmaceutical industry on the 17th, Lilly Korea recently notified Bo
- Company
- Epkinly designated as an orphan drug in Korea
- by Eo, Yun-Ho Jun 19, 2023 06:00am
- Epkinly, the first bispecific antibody drug involving T cells, has been designated as an orphan drug in Korea. The Ministry of Food and Drug Safety recently announced that it designated AbbVie's lymphoma treatment Epkinly as an orphan drug. The specific indication is relapsed or refractory DLBCL with a history of two or more systemic therapie
- Company
- Forxiga generics occupy 20% of mkt 2 mths into their release
- by Kim, Jin-Gu Jun 19, 2023 05:59am
- ‘Forxiga (dapagliflozin)’ generics have increased their market share to 20% within 2 months of entry into the market. With fierce competition unfolding in the prescription field, the total market size expanded to exceed KRW 10 billion per month. However, since so many products were released at the same time, the average monthly prescr
- Company
- Lipiodol is in stable supply despite price cuts
- by Nho, Byung Chul Jun 16, 2023 05:55am
- Guerbet Korea X-ray contrast agent Lipiodol Ultra (iodized oil), which caused controversy over supply and demand, faced a drug price cut due to the entry into a generic on the 1st of last month. Still, it is understood that the supply is stable so far. In the meantime, Guerbet Korea has been negotiating with the health authorities for reasons
